Macrophage-intrinsic phosphoinositide 3-kinase-γ (PI3Kγ) functions as a signaling switch that biases tumor-associated macrophages (TAMs) toward immunosuppression; pharmacologic PI3Kγ inhibition rebalances NF-κB/C/EBPβ programs, enhances antigen-presenting functions, and potentiates PD-(L)1 blockade in preclinical models, supporting clinical evaluation as a combinatorial partner (69, 70). The gene discussed is CD274; the disease is neoplasm.